Avivagen Announces Voting Results for the Election of its Directors
05 April 2014 - 6:59AM
Access Wire
Ottawa, ON / ACCESSWIRE / April
4 2014 / - Avivagen Inc. (TSXV: VIV), a
wellness company developing and delivering products that support
and enhance the health and quality of life for animals and the
people who care for them, announces the results of shareholder
voting for the election of its directors.
Avivagen is pleased to announce that
each of the nominees proposed as directors in the management
information circular dated February 28, 2014 was duly elected as a
director of Avivagen by a majority of the votes cast by
shareholders present in person or by proxy at the Annual Meeting of
Shareholders held in Ottawa, Ontario on April 4, 2014.
The voting results are detailed below:
------------------------------------------------------
|Nominee |% |% Withheld|
| |For | |
|----------------------------------------------------|
|G.F. Kym Anthony |97.3% |2.7% |
|----------------------------------------------------|
|Graham Burton |100.0% |Nil |
|----------------------------------------------------|
|Janusz Daroszewski |100.0% |Nil |
|----------------------------------------------------|
|Cameron L. Groome |97.3% |2.7% |
|----------------------------------------------------|
|David Hankinson |97.4% |2.6% |
|----------------------------------------------------|
|Amin Khalifa |99.9% |0.1% |
|----------------------------------------------------|
|Chandra Panchal |98.8% |1.2% |
------------------------------------------------------
A meeting of the duly appointed Board of
Directors followed the annual general meeting, at which the
directors thanked the Company's retiring Chairman, Mr. Jacques
Brault, for his services to Avivagen and unanimously appointed Mr.
Kym Anthony as the new Chairman.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life
sciences company trading on the TSX Venture Exchange under the
ticker symbol "VIV". The Company's goal is to develop and deliver
scientifically-proven solutions that can truly benefit companion
and production animals by employing natural mechanisms for
maintaining good health. Avivagen's targeted markets include
Livestock Productivity and Pet Wellness.
The company has sites located in partnership
facilities of the National Research Council of Canada (NRC) - in
Ottawa, Ontario and Charlottetown, Prince Edward Island. More
information can be found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected
technology is based on its discoveries concerning carotenoid
antioxidants. The novel natural compounds discovered by Avivagen
support the body's own systems to maintain and enhance health,
particularly by supporting immune function. Avivagen's
commercial-stage application of its technology is Fully-Oxidized
beta-Carotene (OxC-beta). OxC-beta compounds occur naturally as
carotenoid oxidation products in vegetation, but in minute amounts.
They have been developed to support the health of companion animals
and for use in the global food animal market.
Research and study results indicate OxC-beta
supports innate immune function, which can help maintain good
health. In pets, OxC-beta supports overall vitality and energy,
mobility and joint function, skin, coat and gut. Results observed
in food animals have included healthier growth, better utilization
of feed and decreased mortality. In food animals, it is intended
that use of OxC-beta avoids the feeding of antibiotics.
The commercial products of Avivagen are
OxC-beta for livestock, Vivamune(TM) Health Chews and Oximunol(TM)
Chewables.
About OxC-beta for
Livestock
OxC-beta for Livestock is available as a 10%
pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million
addition to animal feeds, in accordance with producer-developed
protocols. In past studies, OxC-beta has been shown to support
health and growth in species such as fish, chicken, pigs and
cattle. OxC-beta for livestock is currently available for
commercial sale in the Kingdom of Thailand.
About Vivamune(TM) Health
Chews - For dogs and cats
Vivamune(TM) Health Chews, containing
Avivagen's proprietary active ingredients, are
scientifically-formulated chews for dogs and cats. Vivamune(TM)
Health Chews work with a pet's own immune system to maintain
overall health and well-being. They are sold in re-sealable
packages of 30 chews and are currently available in the United
States by ordering on-line at
www.vivamunehealth.com.
About Oximunol(TM)
Chewables - For dogs
Oximunol(TM) Chewables are
scientifically-formulated chewable tablets that contain Avivagen's
proprietary, patented active ingredient OxC-beta. OxC-beta has been
shown to stimulate innate cellular immunity and may thereby help to
maintain overall health and well-being. Oximunol(TM) Chewables are
distributed by Bayer Healthcare LLC and are available through
veterinarians for dogs of all ages in the United States.
Forward
Looking Statements
This document includes certain
forward-looking statements that are based upon current
expectations, which involve risks and uncertainties associated with
the business of Avivagen Inc. and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions "will", "anticipate",
"believe", "plan", "estimate", "expect", "intend", and similar
expressions. Forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results or events
to differ materially from current expectations. Unless required by
law, Avivagen Inc. assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
c.groome@avivagen.com
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
-----------------
|Copyright© 2014|
|Avivagen |
-----------------
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
From Feb 2024 to Feb 2025
